Agios Pharmaceuticals Inc.

The sponsor demonstrates significant commitment to advancing treatment options for patients with acute myeloid leukemia and myelodysplastic syndromes. Research initiatives focus on addressing relapsed or refractory disease in adult populations, with particular attention to patients who have exhausted standard therapeutic options. The investigational approaches target specific molecular pathways involved in hematologic malignancies, exploring novel mechanisms that may offer clinical benefit to patients with limited treatment alternatives.

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Relapsed or Refractory Hematologic Cancers

The research portfolio includes trials designed to evaluate therapeutic efficacy in patients who have previously received multiple lines of therapy, addressing a critical unmet need in refractory hematologic conditions.